Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Candel Therapeutics (CADL) EBT Margin (2020 - 2022)

Candel Therapeutics' EBT Margin history spans 3 years, with the latest figure at 25403.23% for Q4 2022.

  • On a quarterly basis, EBT Margin rose 10378011.0% to 25403.23% in Q4 2022 year-over-year; TTM through Dec 2022 was 28395.97%, a 235657.0% decrease, with the full-year FY2022 number at 28169.6%, down 239060.0% from a year prior.
  • EBT Margin hit 25403.23% in Q4 2022 for Candel Therapeutics, up from 29216.13% in the prior quarter.
  • Over the last five years, EBT Margin for CADL hit a ceiling of 8145.16% in Q2 2020 and a floor of 129183.33% in Q4 2021.
  • Historically, EBT Margin has averaged 30672.97% across 3 years, with a median of 25403.23% in 2022.
  • Biggest five-year swings in EBT Margin: plummeted -10958333bps in 2021 and later soared 10378011bps in 2022.
  • Tracing CADL's EBT Margin over 3 years: stood at 19600.0% in 2020, then tumbled by -559bps to 129183.33% in 2021, then surged by 80bps to 25403.23% in 2022.
  • Business Quant data shows EBT Margin for CADL at 25403.23% in Q4 2022, 29216.13% in Q3 2022, and 29412.9% in Q2 2022.